Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report
- 3 July 2020
- journal article
- research article
- Published by Taylor & Francis Ltd in Journal of Dermatological Treatment
- Vol. 31 (5), 446-447
- https://doi.org/10.1080/09546634.2020.1764472
Abstract
This is a report of a case with mucous membrane pemphigoid (MMP) with severe eye involvement and concurrent COVID-19 treated successfully using simultaneous high dose intravenous immunoglobulin (IVIg) and anti-viral treatment as hydroxychloroquine, lopinavir/ritonavir, and ribavirin. He had finished a 2-g cycle of rituximab (RTX) in late January. He was receiving mycophenolate mofetil (MMF) for one month and 30 mg prednisolone for three months until his hospitalization. Prednisolone was tapered to 15 mg when current COVID-19 was suspected, considering his recent cough, dyspnea, and fever.This publication has 3 references indexed in Scilit:
- Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumoniaEmerging Microbes & Infections, 2020
- Postoperative Antifungal Treatment of Pulmonary Cryptococcosis in Non-HIV-Infected and Non-Transplant-Recipient Patients: A Report of 110 Cases and Literature ReviewOpen Forum Infectious Diseases, 2020
- High-Dose Intravenous Immunoglobulin in Skin Autoimmune DiseaseFrontiers in Immunology, 2019